ClinicalTrials.gg
Not yet recruitingNCT07859085Updated Nov 10, 2026

A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma

A Phase 1 interventional study of GDC-7035 and Panitumumab in Colorectal Neoplasms and Pancreatic Ductal Adenocarcinoma, sponsored by Genentech, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

How we know

Updated Nov 10, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
388
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies in Colorectal Neoplasms by Hoffmann-La Roche — 3 open to participants now, 6 under way, none of them phase 3. Colorectal Neoplasms · Hoffmann-La Roche.

Planned enrollment
14th of 77
388 · median 96
Started
2026
with 2 others
Phase 1
22 of 111
3 open now
Registered
111th of 111
by date

Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 14th largest by planned enrollment of the 77 interventional ones that give a count, is one of 3 that started in 2026, is one of 22 in phase 1, and was the 111th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

3 of the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the safety of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with KRAS G12D-mutated metastatic colorectal cancer (CRC) or pancreatic ductal adenocarcinoma (PDAC). The study consists of a safety run-in period followed by a randomized/expansion period.

03

Conditions studied

  • Colorectal Neoplasms
  • Pancreatic Ductal Adenocarcinoma

Keywords

  • KRAS G12D-mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed presence of the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutation as documented through central laboratory testing or prior local laboratory testing
  • Agreement to adhere to the requirements described in the protocol for participants of and participants who produce sperm

Exclusion criteria

Exclusion Criteria:

  • Malabsorption syndrome or other conditions that would interfere with enteral absorption
  • Known and untreated, or active central nervous system (CNS)
  • Known liver disease
  • History of or active clinically significant cardiovascular dysfunction

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
388 participants (estimated)

Study arms

  • Experimental
    Group A: GDC-7035 + mFOLFOX6 + Panitumumab

    Participants with CRC will receive GDC-7035 in combination with modified (levo)leucovorin, 5-fluorouracil (5-FU), oxaliplatin (mFOLFOX6) and panitumumab as per the schedule specified in the protocol during the safety run-in period. Participants in the randomized or expansion period will also receive GDC-7035 in combination with mFOLFOX6 and panitumumab at doses determined to be safe in the safety run-in period.

    Drug: GDC-7035 · Biological: Panitumumab · Drug: mFOLFOX6

  • Experimental
    Group B: GDC-7035 + FOLFIRI + Panitumumab

    Participants with CRC will receive GDC-7035 in combination with leucovorin, 5-FU, irinotecan (FOLFIRI), and panitumumab as per the schedule specified in the protocol during the safety run-in period. Participants in the randomized or expansion period will also receive GDC-7035 in combination with FOLFIRI and panitumumab at doses determined to be safe in the safety run-in period.

    Drug: GDC-7035 · Biological: Panitumumab · Drug: FOLFIRI

  • Experimental
    Group C: GDC-7035 + mFOLFIRINOX or GDC-7035 Monotherapy

    Participants with PDAC will receive GDC-7035 in combination with modified leucovorin, 5-FU, irinotecan, oxaliplatin (mFOLFIRINOX) as per the schedule specified in the protocol during the safety run-in period. Participants in the randomized or expansion period will also receive GDC-7035 as a single agent or in combination with mFOLFIRINOX at doses determined to be safe in the safety run-in period.

    Drug: GDC-7035 · Drug: mFOLFIRINOX

  • Experimental
    Group D: GDC-7035 + Gem-nabP or GDC-7035 Monotherapy

    Participants with PDAC will receive GDC-7035 in combination with gemcitabine and nab-paclitaxel (Gem-nabP) as per the schedule specified in the protocol during the safety run-in period. Participants in the randomized or expansion period will also receive GDC-7035 as a single agent or in combination with Gem-nabP at doses determined to be safe in the safety run-in period.

    Drug: GDC-7035 · Drug: Gem-nabP

Interventions

  • DrugGDC-7035

    Participants will receive GDC-7035 as per the schedule specified in the protocol.

    Also known as: RO7782493

  • BiologicalPanitumumab

    Participants will receive panitumumab in accordance with the local prescribing information.

  • DrugmFOLFOX6

    Participants will receive mFOLFOX6 in accordance with the local prescribing information.

  • DrugFOLFIRI

    Participants will receive FOLFIRI in accordance with the local prescribing information.

  • DrugmFOLFIRINOX

    Participants will receive mFOLFIRINOX in accordance with the local prescribing information.

  • DrugGem-nabP

    Participants will receive Gem-nabP in accordance with the local prescribing information.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Time frame: Up to approximately 30 months

  2. Number of Participants With Key Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to Day 28

Secondary outcomes

  1. Objective Response Rate (ORR)

    Time frame: Up to approximately 30 months

  2. Duration of Response (DOR)

    Time frame: Up to approximately 30 months

  3. Progression-free Survival (PFS) After Randomization

    Time frame: Up to approximately 30 months

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2029, 28 months later.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's planned 28 months is below that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Nov 30, 2026was Oct 2026
Primary completionEst.
Mar 30, 2029
CompletionEst.
Mar 30, 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 31, 2026→Nov 30, 2026
Nov 10, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 3 updates
  1. Nov 10, 2026
    Start date Oct 31, 2026→Nov 30, 2026
    + 1 other change: verification date
  2. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date
  3. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859085
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Mar 30, 2029 (estimated)
Completion
Mar 30, 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Reference Study ID Number: GO46205 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion